Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis

Clinical Immunology

Volumn 142, Issue 2, 2012, Pages 176-193

  Dueckers, Gregor ^a   Guellac, Nihal ^b   Arbogast, Martin ^c   Dannecker, Guenther ^d   Foeldvari, Ivan ^e   Frosch, Michael ^f   Ganser, Gerd ^g   Heiligenhaus, Arnd ^h   Horneff, Gerd ⁱ   Illhardt, Arnold ^g   Kopp, Ina ^j   Krauspe, Ruediger ^k   Markus, Barbara ^l   Michels, Hartmut ^m   Schneider, Matthias ⁿ   Singendonk, Wolfram ^g   Sitter, Helmut ^o   Spamer, Marianne ^m   Wagner, Norbert ^p   Niehues, Tim ^a  

^a HELIOS Children's Hospital   (Germany)

^b BUNDESWEHRZENTRALKRANKENHAUS KOBLENZ   (Germany)

^c Rheumazentrum Oberammergau   (Germany)

^d OLGAHOSPITAL   (Germany)

^e Hamburger Zentrum für Kinder und Jugendrheumatologie   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g St Josef Stift ^*

^h ST FRANZISKUS HOSPITAL   (Germany)

ⁱ Asklepios Children's Hospital   (Germany)

^j Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)   (Germany)

^k University Department of Orthopedics   (Germany)

^l Deutsche Rheuma Liga eV   (Germany)

^m German Centre for Pediatric and Adolescent Rheumatology   (Germany)

ⁿ University Department of Endocrinology Diabetology and Rheumatology   (Germany)

^o PHILIPPS UNIVERSITY MARBURG   (Germany)

^p UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

more..

Author keywords

Children and adolescents; Consensus; Guideline; Juvenile idiopathic arthritis; Treatment

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CELECOXIB; CORTICOSTEROID; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; MELOXICAM; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TRIAMCINOLONE ACETONIDE; TRIAMCINOLONE HEXACETONIDE; TUMOR NECROSIS FACTOR;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BODY WEIGHT; CONSENSUS; DRUG EFFICACY; DRUG PULSE THERAPY; EVIDENCE BASED MEDICINE; EXERCISE; HEALTH CARE QUALITY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL SOCIETY; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; SYNOVECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; WEIGHT BEARING;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; METHOTREXATE; PRACTICE GUIDELINES AS TOPIC; YOUNG ADULT;

EID: 84856555944     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.10.003     Document Type: Article

References (96)

1. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., He X., Maldonado-Cocco J., Orozco-Alcala J., Prieur A.M., Suarez-Almazor M.E., Woo P. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 2004, 31:390-392.
2. Prakken B., Albani S., Martini A. Juvenile idiopathic arthritis. Lancet 2011, 377:2138-2149.
3. April K.T., Feldman D.E., Platt R.W., Duffy C.M. Comparison between children with juvenile idiopathic arthritis (JIA) and their parents concerning perceived quality of life. Qual. Life Res. 2006, 15:655-661.
4. Feldman B.M., Grundland B., McCullough L., Wright V. Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care. J. Rheumatol. 2000, 27:226-233.
5. Packham J.C., Hall M.A. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002, 41:1428-1435.
6. Sandborg C. Pediatric rheumatic disease: standards of care for JIA-the basic foundation for quality. Nat. Rev. Rheumatol. 2010, 6:389-390.
7. Guellac N., Niehues T. Interdisciplinary and evidence-based treatment guideline for juvenile idiopathic arthritis. Klin. Padiatr. 2008, 220:392-402.
8. Schnakenburg K. Leitlinien in der Kinder- und Jugendmedizin 2005, Elsevier, pp. H1: 1-15.
9. Juni P., Nartey L., Reichenbach S., Sterchi R., Dieppe P.A., Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004, 364:2021-2029.
10. Feldman W. Evidence-based Pediatrics 2000, BC Deckers, Hamilton. 1st ed.
11. Van de Ven A.H., Delbecq A.L. The nominal group as a research instrument for exploratory health studies. Am. J. Public Health 1972, 62:337-342.
12. Linstone H.A., Turoff M. The Delphi Method: Techniques and Applications 1975, Addison-Wesley Pub.
13. Kvien T.K., Hoyeraal H.M., Sandstad B. Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis. Assessment of tolerance and efficacy in a single-centre 24-week double-blind parallel study. Scand. J. Rheumatol. 1984, 13:342-350.
14. Laxer R.M., Silverman E.D., St-Cyr C., Tran M.T., Lingam G. A six-month open safety assessment of a naproxen suspension formulation in the therapy of juvenile rheumatoid arthritis. Clin. Ther. 1988, 10:381-387.
15. Leak A.M., Richter M.R., Clemens L.E., Hall M.A., Ansell B.M. A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis. Clin. Exp. Rheumatol. 1988, 6:157-160.
16. Haapasaari J., Wuolijoki E., Ylijoki H. Treatment of juvenile rheumatoid arthritis with diclofenac sodium. Scand. J. Rheumatol. 1983, 12:325-330.
17. Giannini E.H., Brewer E.J., Miller M.L., Gibbas D., Passo M.H., Hoyeraal H.M., Bernstein B., Person D.A., Fink C.W., Sawyer L.A., et al. Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. J. Pediatr. 1990, 117:645-652.
18. Stoeber E., Sanger L. Experiences with indomethacin in long-term therapy of juvenile rheumatoid arthritis. Arzneimittelforschung 1971, 21:1865-1866.
19. Ruperto N., Nikishina I., Pachanov E.D., Shachbazian Y., Prieur A.M., Mouy R., Joos R., Zulian F., Schwarz R., Artamonova V., Emminger W., Bandeira M., Buoncompagni A., Foeldvari I., Falcini F., Baildam E., Kone-Paut I., Alessio M., Gerloni V., Lenhardt A., Martini A., Hanft G., Sigmund R., Simianer S. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum. 2005, 52:563-572.
20. Foeldvari I., Szer I.S., Zemel L.S., Lovell D.J., Giannini E.H., Robbins J.L., West C.R., Steidle G., Krishnaswami S., Bloom B.J. A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. J. Rheumatol. 2009, 36:174-182.
21. Zulian F., Martini G., Gobber D., Agosto C., Gigante C., Zacchello F. Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2003, 42:1254-1259.
22. Zulian F., Martini G., Gobber D., Plebani M., Zacchello F., Manners P. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology (Oxford) 2004, 43:1288-1291.
23. Habib G.S. Systemic effects of intra-articular corticosteroids. Clin. Rheumatol. 2009, 28:749-756.
24. Kirwan J.R. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N. Engl. J. Med. 1995, 333:142-146.
25. Michels H. What is low-dose corticosteroid therapy in juvenile idiopathic arthritis? A worldwide, questionnaire-based survey. Z. Rheumatol. 2000, 59(Suppl. 2). II/127-130.
26. Miller J.J. Prolonged use of large intravenous steroid pulses in the rheumatic diseases of children. Pediatrics 1980, 65:989-994.
27. Picco P., Gattorno M., Buoncompagni A., Pistoia V., Borrone C. 6-methylprednisolone 'mini-pulses': a new modality of glucocorticoid treatment in systemic onset juvenile chronic arthritis. Scand. J. Rheumatol. 1996, 25:24-27.
28. Prieur A.M. The place of corticosteroid therapy in juvenile chronic arthritis in 1992. J. Rheumatol. Suppl. 1993, 37:32-34.
29. Gao J.S., Wu H., Tian J. Treatment of patients with juvenile rheumatoid arthritis with combination of leflunomide and methotrexate. Zhonghua Er Ke Za Zhi 2003, 41:435-438.
30. Niehues T., Horneff G., Michels H., Hock M.S., Schuchmann L. Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria. Rheumatol. Int. 2005, 25:169-178.
31. Ruperto N., Lovell D.J., Cuttica R., Wilkinson N., Woo P., Espada G., Wouters C., Silverman E.D., Balogh Z., Henrickson M., Apaz M.T., Baildam E., Fasth A., Gerloni V., Lahdenne P., Prieur A.M., Ravelli A., Saurenmann R.K., Gamir M.L., Wulffraat N., Marodi L., Petty R.E., Joos R., Zulian F., McCurdy D., Myones B.L., Nagy K., Reuman P., Szer I., Travers S., Beutler A., Keenan G., Clark J., Visvanathan S., Fasanmade A., Raychaudhuri A., Mendelsohn A., Martini A., Giannini E.H. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007, 56:3096-3106.
32. Visser K., van der Heijde D.M. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin. Exp. Rheumatol. 2009, 27:1017-1025.
33. Cespedes-Cruz A., Gutierrez-Suarez R., Pistorio A., Ravelli A., Loy A., Murray K.J., Gerloni V., Wulffraat N., Oliveira S., Walsh J., Penades I.C., Alpigiani M.G., Lahdenne P., Saad-Magalhaes C., Cortis E., Lepore L., Kimura Y., Wouters C., Martini A., Ruperto N. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann. Rheum. Dis. 2008, 67:309-314.
34. Kvien T.K., Hoyeraal H.M., Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J. Rheumatol. 1986, 13:118-123.
35. Silverman E., Mouy R., Spiegel L., Jung L.K., Saurenmann R.K., Lahdenne P., Horneff G., Calvo I., Szer I.S., Simpson K., Stewart J.A., Strand V. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N. Engl. J. Med. 2005, 352:1655-1666.
36. van Rossum M.A., Fiselier T.J., Franssen M.J., Zwinderman A.H., ten Cate R., van Suijlekom-Smit L.W., van Luijk W.H., van Soesbergen R.M., Wulffraat N.M., Oostveen J.C., Kuis W., Dijkstra P.F., van Ede C.F., Dijkmans B.A. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. 1998, 41:808-816.
37. van Rossum M.A., van Soesbergen R.M., Boers M., Zwinderman A.H., Fiselier T.J., Franssen M.J., ten Cate R., van Suijlekom-Smit L.W., Wulffraat N.M., van Luijk W.H., Oostveen J.C., Kuis W., Dijkmans B.A. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann. Rheum. Dis. 2007, 66:1518-1524.
38. Lovell D.J., Giannini E.H., Reiff A., Cawkwell G.D., Silverman E.D., Nocton J.J., Stein L.D., Gedalia A., Ilowite N.T., Wallace C.A., Whitmore J., Finck B.K. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 2000, 342:763-769.
39. Lovell D.J., Reiff A., Jones O.Y., Schneider R., Nocton J., Stein L.D., Gedalia A., Ilowite N.T., Wallace C.A., Whitmore J.B., White B., Giannini E.H. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006, 54:1987-1994.
40. Lovell D.J., Ruperto N., Goodman S., Reiff A., Jung L., Jarosova K., Nemcova D., Mouy R., Sandborg C., Bohnsack J., Elewaut D., Foeldvari I., Gerloni V., Rovensky J., Minden K., Vehe R.K., Weiner L.W., Horneff G., Huppertz H.I., Olson N.Y., Medich J.R., Carcereri-De-Prati R., McIlraith M.J., Giannini E.H., Martini A. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 2008, 359:810-820.
41. Prince F.H., Twilt M., ten Cate R., van Rossum M.A., Armbrust W., Hoppenreijs E.P., van Santen-Hoeufft M., Koopman-Keemink Y., Wulffraat N.M., van Suijlekom-Smit L.W. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch National Register. Ann. Rheum. Dis. 2009, 68:635-641.
42. Diak P., Siegel J., La Grenade L., Choi L., Lemery S., McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010, 62:2517-2524.
43. Horneff G., Hospach T., Dannecker G., Foll D., Haas J.P., Girschick H.J., Huppertz H.I., Keitzer R., Laws H.J., Michels H., Minden K., Trauzeddel R. Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009. Z. Rheumatol. 2010, 69:561-567.
44. Hospach T., Haas J.P., Huppertz H.I., Keitzer R., Michels H., Trauzeddl R., Foll D., Dannecker G., Horneff G. Comment of the Society of Pediatric and Adolescent Rheumatology on the US Food and Drug Administration (FDA) announcement regarding cases of malignancy in anti-TNF-treated patients. Z. Rheumatol. 2009, 68:162-164.
45. Lovell D.J., Reiff A., Ilowite N.T., Wallace C.A., Chon Y., Lin S.L., Baumgartner S.W., Giannini E.H. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008, 58:1496-1504.
46. Giannini E.H., Ilowite N.T., Lovell D.J., Wallace C.A., Rabinovich C.E., Reiff A., Higgins G., Gottlieb B., Singer N.G., Chon Y., Lin S.L., Baumgartner S.W. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009, 60:2794-2804.
47. Horneff G., Schmeling H., Biedermann T., Foeldvari I., Ganser G., Girschick H.J., Hospach T., Huppertz H.I., Keitzer R., Kuster R.M., Michels H., Moebius D., Rogalski B., Thon A. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann. Rheum. Dis. 2004, 63:1638-1644.
48. Prince F.H., Twilt M., Simon S.C., van Rossum M.A., Armbrust W., Hoppenreijs E.P., Kamphuis S., van Santen-Hoeufft M., Koopman-Keemink Y., Wulffraat N.M., ten Cate R., van Suijlekom-Smit L.W. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann. Rheum. Dis. 2009, 68:1228-1229.
49. Horneff G., De Bock F., Foeldvari I., Girschick H.J., Michels H., Moebius D., Schmeling H. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann. Rheum. Dis. 2009, 68:519-525.
50. Ilowite N., Porras O., Reiff A., Rudge S., Punaro M., Martin A., Allen R., Harville T., Sun Y.N., Bevirt T., Aras G., Appleton B. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin. Rheumatol. 2009, 28:129-137.
51. Lequerre T., Quartier P., Rosellini D., Alaoui F., De Bandt M., Mejjad O., Kone-Paut I., Michel M., Dernis E., Khellaf M., Limal N., Job-Deslandre C., Fautrel B., Le Loet X., Sibilia J. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 2008, 67:302-308.
52. Gattorno M., Piccini A., Lasiglie D., Tassi S., Brisca G., Carta S., Delfino L., Ferlito F., Pelagatti M.A., Caroli F., Buoncompagni A., Viola S., Loy A., Sironi M., Vecchi A., Ravelli A., Martini A., Rubartelli A. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008, 58:1505-1515.
53. Yokota S., Imagawa T., Mori M., Miyamae T., Aihara Y., Takei S., Iwata N., Umebayashi H., Murata T., Miyoshi M., Tomiita M., Nishimoto N., Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371:998-1006.
54. Ruperto N., Lovell D.J., Quartier P., Paz E., Rubio-Perez N., Silva C.A., Abud-Mendoza C., Burgos-Vargas R., Gerloni V., Melo-Gomes J.A., Saad-Magalhaes C., Sztajnbok F., Goldenstein-Schainberg C., Scheinberg M., Penades I.C., Fischbach M., Orozco J., Hashkes P.J., Hom C., Jung L., Lepore L., Oliveira S., Wallace C.A., Sigal L.H., Block A.J., Covucci A., Martini A., Giannini E.H. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008, 372:383-391.
55. Ruperto N., Lovell D.J., Quartier P., Paz E., Rubio-Perez N., Silva C.A., Abud-Mendoza C., Burgos-Vargas R., Gerloni V., Melo-Gomes J.A., Saad-Magalhaes C., Chavez-Corrales J., Huemer C., Kivitz A., Blanco F.J., Foeldvari I., Hofer M., Horneff G., Huppertz H.I., Job-Deslandre C., Loy A., Minden K., Punaro M., Nunez A.F., Sigal L.H., Block A.J., Nys M., Martini A., Giannini E.H. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010, 62:1792-1802.
56. Brinkman D.M., de Kleer I.M., ten Cate R., van Rossum M.A., Bekkering W.P., Fasth A., van Tol M.J., Kuis W., Wulffraat N.M., Vossen J.M. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum. 2007, 56:2410-2421.
57. Klepper S.E. Effects of an eight-week physical conditioning program on disease signs and symptoms in children with chronic arthritis. Arthritis Care Res. 1999, 12:52-60.
58. Singh-Grewal D., Schneiderman-Walker J., Wright V., Bar-Or O., Beyene J., Selvadurai H., Cameron B., Laxer R.M., Schneider R., Silverman E.D., Spiegel L., Tse S., Leblanc C., Wong J., Stephens S., Feldman B.M. The effects of vigorous exercise training on physical function in children with arthritis: a randomized, controlled, single-blinded trial. Arthritis Rheum. 2007, 57:1202-1210.
59. Stephens S., Singh-Grewal D., Bar-Or O., Beyene J., Cameron B., Leblanc C.M., Schneider R., Schneiderman-Walker J., Selvadurai H., Silverman E., Spiegel L., Tse S.M., Wright V., Feldman B.M. Reliability of exercise testing and functional activity questionnaires in children with juvenile arthritis. Arthritis Rheum. 2007, 57:1446-1452.
60. Takken T., van der Net J., Kuis W., Helders P.J. Physical activity and health related physical fitness in children with juvenile idiopathic arthritis. Ann. Rheum. Dis. 2003, 62:885-889.
61. Toledo M.M., Martini G., Gigante C., Da Dalt L., Tregnaghi A., Zulian F. Is there a role for arthroscopic synovectomy in oligoarticular juvenile idiopathic arthritis?. J. Rheumatol. 2006, 33:1868-1872.
62. de Benedetti F., Brunner H., Ruperto N., Wright S., Kenwright A., Cuttica R., Woo P., Schneider R., Lovell D.J., Martini A. Efficacy and safety of Tocilizumab in patients with systemic juvenile idiopathic arthritis (sJIA): 12-week data from the phase III TENDER trial. Ann. Rheum. Dis. 2010, 69:146.
63. Quartier P., Allantaz F., Cimaz R., Pillet P., Messiaen C., Bardin C., Bossuyt X., Boutten A., Bienvenu J., Duquesne A., Richer O., Chaussabel D., Mogenet A., Banchereau J., Treluyer J.M., Landais P., Pascual V. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 2011, 70:747-754.
64. Furst D.E., Keystone E.C., Braun J., Breedveld F.C., Burmester G.R., De Benedetti F., Dorner T., Emery P., Fleischmann R., Gibofsky A., Kalden J.R., Kavanaugh A., Kirkham B., Mease P., Sieper J., Singer N.G., Smolen J.S., Van Riel P.L., Weisman M.H., Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann. Rheum. Dis. 2010, 70(Suppl. 1):i2-i36.
65. Beukelman T., Patkar N.M., Saag K.G., Tolleson-Rinehart S., Cron R.Q., Dewitt E.M., Ilowite N.T., Kimura Y., Laxer R.M., Lovell D.J., Martini A., Rabinovich C.E., Ruperto N. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011, 63:465-482. (Hoboken).
66. Simard J.F., Neovius M., Hagelberg S., Askling J. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum. 2010, 62:3776-3782.
67. Imagawa T., Yokota S., Mori M., Miyamae T., Takei S., Imanaka H., Nerome Y., Iwata N., Murata T., Miyoshi M., Nishimoto N., Kishimoto T. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod. Rheumatol. 2011, 10.2007/s10165-011-0481-0.
68. Shaneyfelt T.M., Mayo-Smith M.F., Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. Jama 1999, 281:1900-1905.
69. Grilli R., Magrini N., Penna A., Mura G., Liberati A. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet 2000, 355:103-106.
70. Burgers J.S., Grol R., Klazinga N.S., Makela M., Zaat J. Towards evidence-based clinical practice: an international survey of 18 clinical guideline programs. Int. J. Qual. Health Care 2003, 15:31-45.
71. Cassidy J.T., Petty R.E. Juvenile Idiopathic Rheumatic Arthritis 2005, WB Saunders, Philadelphia. 5th Edition.
72. Lehman T.J. Are withdrawal trials in paediatric rheumatic disease helpful?. Lancet 2008, 372:348-350.
73. Munro J. Recommendations for the Diagnosis and Management of Juvenile Idiopathic Arthritis 2009, 1-38. The Royal Australian College of General Practitioners, South Melbourne, http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp119-juvenile-arthritis.pdf.
74. Santos M.J., Fonseca J.E., Canhao H., Conde M., Jose Vieira M., Costa L., Costa M., Salgado M., Melo Gomes J.A. Guidelines for prescribing and monitoring biologic therapies in juvenile idiopathic arthritis. Acta Reumatol. Port. 2007, 32:43-47.
75. Yokota S., Mori M., Imagawa T., Murata T., Tomiita M., Itoh Y., Fujikawa S., Takei S. Guidelines on the use of etanercept for juvenile idiopathic arthritis in Japan. Mod. Rheumatol. 2010, 20:107-113.
76. Appraisal of Guidelines for Research & Evaluation (AGREE) instrument The AGREE Collaboration. http://www.agreecollaboration.org.
77. Kopp I., Thole H., Langer T., Selbmann H.K., Ollenschläger G. German Instrument for Methodological Guideline Appraisal (DELBI) http://www.versorgungsleitlinien.de.
78. Ä.Ärztliches Zentrum für Qualität in der Medizin A. Arbeitsgemeinschaften der Wissenschaftlichen Fachgesellschaften in der Medizin, Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI) Fassung 2005/2006. Z. Ärztl. Fortbild. Qualitätssich. 2005, 99:468-519.
79. de Wit M.P., Berlo S.E., Aanerud G.J., Aletaha D., Bijlsma J.W., Croucher L., Da Silva J.A., Glusing B., Gossec L., Hewlett S., Jongkees M., Magnusson D., Scholte-Voshaar M., Richards P., Ziegler C., Abma T.A. European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. Ann. Rheum. Dis. 2011, 70:722-726.
80. Foeldvari I., Bidde M. Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis. International League of Associations for Rheumatology. J. Rheumatol. 2000, 27:1069-1072.
81. Merino R., de Inocencio J., Garcia-Consuegra J. Evaluation of revised International League of Associations for Rheumatology classification criteria for juvenile idiopathic arthritis in Spanish children (Edmonton 2001). J. Rheumatol. 2005, 32:559-561.
82. Ramsey S.E., Bolaria R.K., Cabral D.A., Malleson P.N., Petty R.E. Comparison of criteria for the classification of childhood arthritis. J. Rheumatol. 2000, 27:1283-1286.
83. Horneff G., Ebert A., Fitter S., Minden K., Foeldvari I., Kummerle-Deschner J., Thon A., Girschick H.J., Weller F., Huppertz H.I. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford) 2009, 48:916-919.
84. Giannini E.H., Brewer E.J., Kuzmina N., Shaikov A., Maximov A., Vorontsov I., Fink C.W., Newman A.J., Cassidy J.T., Zemel L.S. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N. Engl. J. Med. 1992, 326:1043-1049.
85. Ravelli A., Viola S., Migliavacca D., Ruperto N., Pistorio A., Martini A. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J. Pediatr. 1999, 135:316-320.
86. Woo P., Southwood T.R., Prieur A.M., Dore C.J., Grainger J., David J., Ryder C., Hasson N., Hall A., Lemelle I. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000, 43:1849-1857.
87. Silverman E., Spiegel L., Hawkins D., Petty R., Goldsmith D., Schanberg L., Duffy C., Howard P., Strand V. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2005, 52:554-562.
88. Lovell D.J., Giannini E.H., Kimura Y., Suzanne C., Hashkes P.J., Reiff A. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum. 2009, 60.
89. Ruperto N., Quartier P., Wulffraat N., Woo P., Loy A., Mouy R., Bader-Meunier B., Prakken B.J., Noseda E., Belleli R., Lecot J., Rordorf C., Martini A. A Phase II Trial with canakinumab (ACZ885), a new IL-1-beta blocking monoclonal antibody, to evaluate safety and preliminary efficacy in children with systemic juvenile idiopathic arthritis. Ann. Rheum. Dis. 2009, 68:170.
90. Lovell D.J., Giannini E.H., Kimura Y., et al. Preliminary evidence for bioactivity of IL-1 trap (Rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum. 2006, 54:S325.
91. Lovell D.J., Giannini E.H., Kimura Y., et al. Preliminary evidence for sustained bioactivity of IL-1 Trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007, 56:S514.
92. Ruperto N., De Benedetti F., Brunner H., Allen R., Brown D., Chaitow J., Cortis E., Espada G., Flato B., Gerloni V., Horneff G., Wright S., Kenwright A., Schneider R., Woo P., Martini A., Lovell D.J. Tocilizumab is efficacious in patients with systemic juvenile idiopathic arthritis (sJIA) across baseline disease characteristics and prior/baseline treatments: 12-week data from the phase II TENDER trial. 17th PReS Congress, Valencia, Spain, 2010 2010.
93. Ruperto N., Lovell D.J., Li T., Sztajnbok F., Goldenstein-Schainberg C., Scheinberg M., Penades I.C., Fischbach M., Orozco J., Hashkes P.J., Hom C., Jung L., Lepore L., Oliveira S., Wallace C., Alessio M., Quartier P., Cortis E., Eberhard A., Simonini G., Lemelle I., Chalom E., Sigal L.H., Block A., Covucci A., Nys M., Martini A., Giannini E.H. Abatacept improves health-related quality of life, pain, sleep quality and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2010, 62(11):1542-1551.
94. Ruperto N., Lovell D.J., Quartier P., Paz E., Rubio-Perez N., Silva C.A., Abud-Mendoza C., Burgos-Vargas R., Gerloni V., Melo-Gomes J.A., Saad-Magalhaes C., Chavez J., Huemer C., Kivitz A., Blanco F.J., Foeldvari I., Hofer M., Horneff G., Huppertz H.I., Deslandre C.J., Loy A., Minden K., Punaro M., Nunez A.F., Sigal L.H., Block A.J., Nys M., Martini A., Giannini E.H. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010, 62:1792-1802.
95. Munro J. Juvenile Idiopathic Arthritis Management Guidelines (Provisional) 2006, Australian Paediatric Rheumatology Group, http://www.nhmrc.gov.au/.
96. Fitch K., Bernstein S.J., Aguilar M.D., Burnand B., LaCalle J.R., Lazaro P., van het Loo M., McDonnell J., Vader J.P., Kahan J.P. The RAND/UCLA Appropriateness Method User's Manual 2000, RAND, Pittsburgh.